Disease Progression in Parkinson Subtypes: the PPMI Dataset
Overview
Affiliations
Introduction: Discrete patterns of progression have been suggested for patients with Parkinson disease and presenting tremor dominant (TD) or postural instability gait disorders (PIGD). However, longitudinal prospective assessments need to take into consideration the variability in clinical manifestations and the evidence that only 40% of initially classified PIGD remain in this subtype at subsequent visits.
Methods: We analyzed clinical progression of PIGD compared to TD using longitudinal clinical data from the PPMI. Given the reported instability of such clinical classification, we only included patients who were reported as PIGD/TD at each visit during the 4-year observation. We used linear mixed-effects models to test differences in progression in these subgroups in 51 dependent variables.
Results: There were 254 patients with yearly assessment. The number of PIGD was 36/254 vs 144/254 TD. PIGD had more severe motor disease at baseline but progressed faster than TD only in three non-motor items of the MDS-UPDRS: cognitive impairment, hallucinations, and psychosis plus features of DDS. Our analysis also showed in PIGD faster increase in the average time with dyskinesia.
Conclusions: PIGD are characterized by more severe disease manifestations at diagnosis and greater cognitive progression, more frequent hallucinations, psychosis as well as features of DDS than TD patients. We interpret these findings as expression of greater cortical and subcortical involvement in PIGD already at onset. Since PIGD/TD classification is very unstable at onset, our analysis based on stricter definition criteria provides important insight for clinical trial stratification and definition of related outcome measures.
Chaudhry F, Kim T, Elemento O, Betel D medRxiv. 2025; .
PMID: 39763525 PMC: 11703317. DOI: 10.1101/2024.12.21.24313256.
Medication recommendation for Parkinson's disease based on dynamics of symptom progression.
Oh M, Kim H, Lee H Sci Rep. 2024; 14(1):25051.
PMID: 39443590 PMC: 11499640. DOI: 10.1038/s41598-024-76941-6.
Ajalin R, Al-Abdulrasul H, Tuisku J, Hirvonen J, Lahdenpohja S, Rinne J Mov Disord. 2024; 40(1):163-167.
PMID: 39435606 PMC: 11752992. DOI: 10.1002/mds.30042.
Huyen Thi Dang T, Truong D, Vinh Nguyen K, Le Ngoc Ha U, Chung Ngoc Vo K, Nguyen T Clin Park Relat Disord. 2024; 11:100270.
PMID: 39318472 PMC: 11420436. DOI: 10.1016/j.prdoa.2024.100270.
Bath J, Wang D Neurotherapeutics. 2024; 21(3):e00354.
PMID: 38579454 PMC: 11000188. DOI: 10.1016/j.neurot.2024.e00354.